Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer


Background:Angiogenesis is fundamental to the progression of many solid tumours including prostate cancer. Sodium selenate is a small, water-soluble, orally bioavailable activator of PP2A phosphatase with anti-angiogenic properties.Methods:This was a dose-escalation phase I study in men with asymptomatic, chemotherapy-naïve, castration-resistant prostate… (More)
DOI: 10.1038/sj.bjc.6605798


6 Figures and Tables